Literature DB >> 17268017

Accuracy of PET/CT in characterization of solitary pulmonary lesions.

Shanna K Kim1, Martin Allen-Auerbach, Jonathan Goldin, Barbara J Fueger, Magnus Dahlbom, Matthew Brown, Johannes Czernin, Christiaan Schiepers.   

Abstract

UNLABELLED: Characterization of a pulmonary lesion is a well-established indication for metabolic imaging with 18F-FDG. There is extensive literature on the use of PET and CT in the characterization of a solitary pulmonary nodule (SPN). The performance of dual-modality imaging with PET/CT for characterizing SPNs was investigated in a clinical referral setting.
METHODS: We performed a retrospective study involving patients referred for SPN characterization with PET/CT between September 2002 and June 2004, for whom a pathologic diagnosis was available. The group consisted of 12 men and 30 women whose age ranged from 35 to 84 y (mean age +/- SD, 67 +/- 11 y). A dual-slice CT/lutetium oxyorthosilicate PET system was used for imaging. CT images were acquired without intravenous contrast. Blinded interpretation was performed by 1 chest radiologist for CT and 2 nuclear medicine physicians for PET. PET/CT images were read in consensus. Lesions were analyzed by location, texture, axial dimension, and metabolic activity and visually scored on a 5-point scale from benign to malignant; the maximum standardized uptake value (SUVmax) was measured.
RESULTS: Lesion diameter varied from 7 to 30 mm (mean +/- SD, 15 +/- 6 mm). The SUVmax ranged from 0.5 to 17.2 (mean +/- SD, 3.0 +/- 3.0). SUVmax corrected for lean body mass was 0.4-12.1 (mean +/- SD, 2.1 +/- 2.0). Comparison of CT versus PET versus PET/CT yielded accuracies of 74%, 74%, and 93%, respectively. PET and CT correctly characterized 31 and PET/CT correctly characterized 39 of the 42 lesions as malignant or benign. The sensitivity and specificity for CT, PET, and PET/CT was 93%/31%, 69%/85%, and 97%/85%, respectively. There were significant differences (P < 0.05) between PET/CT and PET for accuracy, sensitivity, and specificity. Accuracy did not improve by quantitative analysis using an SUVmax cutoff of 2.0 for malignancy. Lean body mass correction of the SUVmax did not change accuracy.
CONCLUSION: PET/CT demonstrates an excellent performance in classifying SPNs as benign or malignant. The combination of anatomic and metabolic imaging is synergistic by maintaining the sensitivity of CT and the specificity of PET, resulting in an overall significantly improved accuracy. Visual interpretation is sufficient for characterizing an SPN. Quantitative analysis does not improve accuracy of PET/CT for SPN characterization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17268017

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  78 in total

Review 1.  Positron emission tomography for benign and malignant disease.

Authors:  Anthony Visioni; Julian Kim
Journal:  Surg Clin North Am       Date:  2011-02       Impact factor: 2.741

2.  Comparison between two super-resolution implementations in PET imaging.

Authors:  Guoping Chang; Tinsu Pan; Feng Qiao; John W Clark; Osama R Mawlawi
Journal:  Med Phys       Date:  2009-04       Impact factor: 4.071

3.  18F-FDG PET/CT diagnostic performance in solitary and multiple pulmonary nodules detected in patients with previous cancer history: reports of 182 nodules.

Authors:  Silvia Taralli; Valentina Scolozzi; Massimiliano Foti; Sara Ricciardi; Anna Rita Forcione; Giuseppe Cardillo; Maria Lucia Calcagni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-08       Impact factor: 9.236

4.  Quantitative and qualitative assessment of non-contrast-enhanced pulmonary MR imaging for management of pulmonary nodules in 161 subjects.

Authors:  Hisanobu Koyama; Yoshiharu Ohno; Atsushi Kono; Daisuke Takenaka; Yoshimasa Maniwa; Yoshihiro Nishimura; Chiho Ohbayashi; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2008-05-06       Impact factor: 5.315

5.  Solitary pulmonary nodule-a case of peripheral adenocarcinoma with rapid metastasis.

Authors:  Chun-Hua Xu; Ping Zhan; Li-Ke Yu
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

Review 6.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

7.  Safety and effectiveness of stereotactic body radiotherapy for a clinically diagnosed primary stage I lung cancer without pathological confirmation.

Authors:  Katsuyuki Sakanaka; Yukinori Matsuo; Yasushi Nagata; Sayo Maki; Keiko Shibuya; Yoshiki Norihisa; Masaru Narabayashi; Nami Ueki; Takashi Mizowaki; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

8.  Performance of integrated FDG-PET/CT for differentiating benign and malignant lung lesions--results from a large prospective clinical trial.

Authors:  Sandra Pauls; Andreas K Buck; Gisela Halter; Felix M Mottaghy; Rainer Muche; Christina Bluemel; Susanne Gerstner; Stefan Krüger; Gerhard Glatting; Ludger Sunder-Plassmann; Peter Möller; Hans-Jürgen Brambs; Sven N Reske
Journal:  Mol Imaging Biol       Date:  2008-01-16       Impact factor: 3.488

9.  Contribution of nonattenuation-corrected images on FDG-PET/CT in the assessment of solitary pulmonary nodules.

Authors:  Ertan Şahin; Ahmet Kara; Umut Elboğa
Journal:  Radiol Med       Date:  2016-08-27       Impact factor: 3.469

Review 10.  PET/CT in oncology: for which tumours is it the reference standard?

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.